Immunomedics, Inc. (NASDAQ:IMMU)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.

Results 1 - 20 of 33 : 1 2 Next »

Recs

0
Member Avatar TerryFool (< 20) Submitted: 3/25/2014 5:50:51 AM : Outperform Start Price: $3.88 IMMU Score: -0.08

BUY@ 4.0 TP 7

Recs

0
Member Avatar TerryHoodSr (46.39) Submitted: 3/24/2014 6:51:27 PM : Outperform Start Price: $4.07 IMMU Score: -3.55

SPEC BUY@ 4.1 TP 7

Recs

0
Member Avatar arbeburns (< 20) Submitted: 1/21/2014 8:24:38 PM : Outperform Start Price: $5.58 IMMU Score: -31.37

great space and great potential

Recs

0
Member Avatar richienorker (< 20) Submitted: 9/27/2013 11:29:32 AM : Outperform Start Price: $6.29 IMMU Score: -48.14

Feel that new drugs will push this stock higher in next few minths.

Recs

0
Member Avatar Jherie66 (52.55) Submitted: 6/29/2013 3:09:43 PM : Outperform Start Price: $4.73 IMMU Score: -36.16

Just feels rite

Recs

4
Member Avatar zzlangerhans (99.73) Submitted: 5/25/2013 7:19:12 AM : Underperform Start Price: $3.21 IMMU Score: -10.11

I just reviewed six years worth of quarterly notes on Immunomedics from my database and all I was left with was a vague sensation of confusion and vertigo. It's absolutely amazing how little concrete progress the company has made in six years. Early and midstage trials are completed with supposedly positive results yet no follow-up trials are ever initiated. Some trials vanish from quarterly calls while still supposedly in progress. The only phase III program, eptratuzumab for lupus, likewise appears and disappears from company PR. In the latest call, the CEO identified the phase I compound clivatuzumab as the company's top priority despite the fact that the phase III EMBODY trials of epratuzumab in lupus will be generating topline data in H1 2014. Doesn't bode well.

The stock is now breaking out sharply from a recent depression at the 2.4 level but the only catalyst prior to the breakout was an announcement of some patents. I'm no patent expert, but I know biopharmas announce patents all the time and they're rarely market-moving events. I smell stirrapulation and I don't see any upcoming developments to sustain the upward trend.

Recs

0
Member Avatar rocknpopstocks (< 20) Submitted: 1/28/2011 12:47:04 PM : Outperform Start Price: $3.26 IMMU Score: -26.15

Could show solid growth Sling'n them legal life savers and thrills.

Recs

0
Member Avatar LuckyShad (74.07) Submitted: 5/25/2010 3:52:30 PM : Outperform Start Price: $3.29 IMMU Score: -54.78

There were 50 items in your list. Here they are in random order:

1 APOL 2S
CBPO (ALREADY PICKED)
2 AFAM 5S
3 IMMU 3*
4 TNDM 5*
AMED
RAI
VPHM
SNTS
CNU
SOLR
IDCC
HRB
UNTD
UEPS
CHKE
SOHU
DECK
OSK
PDLI
NSR
CBI
LO
CYTK
TTT
JCOM
MHP
CHOP
EME
RGR
CSKI
RTN
UIS
ENDP
PRSC
IPXL
VALU
USMO
ELNK
GME
FWLT
CF
ARO
TSRA
MRX
CBST
PPD
DLX
FLR
LIWA
Timestamp: 2010-05-25 19:32:44 UTC

Recs

0
Member Avatar BullishBilly (37.15) Submitted: 4/10/2010 6:35:07 PM : Outperform Start Price: $3.57 IMMU Score: -46.60

Relative to its industry, it has a high earnings yield. Also, strong earnings per share growth is predicted this year.

Recs

0
Member Avatar rasta999 (< 20) Submitted: 3/23/2010 5:50:51 PM : Outperform Start Price: $3.49 IMMU Score: -47.91

drugs in pipeline

Recs

0
Member Avatar connorsdad418 (< 20) Submitted: 3/10/2010 5:40:53 PM : Outperform Start Price: $3.50 IMMU Score: -51.16

timeframe is a bit long here...i actually believe IMMU will see significant PPS increases about a year sooner but there will be big gains in that four year period overall. greatly situated in the sectors that will see obscene amounts of private and public cash thrown at it, specifically immunotherapy and cancer treatments.

Recs

0
Member Avatar itistime2save (< 20) Submitted: 3/3/2010 10:41:56 PM : Outperform Start Price: $3.37 IMMU Score: -50.16

adding to my position Any opinions?

Recs

0
Member Avatar mrsrmc (< 20) Submitted: 10/16/2009 5:22:58 PM : Outperform Start Price: $4.95 IMMU Score: -91.51

There is a vast underreported and researched arm of health care - auto immune dieases and pain care. Plus factopr in "health care reform" mutant viruses running away with headlines, I think this will be one of the companies perking up into the limelight.

Recs

0
Member Avatar goneskuba (24.86) Submitted: 8/31/2009 4:40:45 PM : Underperform Start Price: $5.39 IMMU Score: +110.49

phase ii trials are a long long way away from late phase iii trials...its appears that HGSI might have gotten the lead on a monclonal SLE drug (HGSI might even get the green light and get fast tracked thru the FDA approval process and to market after this november when they release their data)...it seems that gsk might have actually lost out!!!

All this leaves IMMU in the dust...and one drug a company does not make, esp a drug to market coming in second

Recs

0
Member Avatar stocoptions (< 20) Submitted: 8/27/2009 9:46:31 PM : Outperform Start Price: $6.50 IMMU Score: -118.64

good technology

Recs

0
Member Avatar coachinfool (< 20) Submitted: 8/23/2009 8:18:31 AM : Outperform Start Price: $4.12 IMMU Score: -86.05

No longer using cash to fuel its Bunson burners and has promising results in the pipeline and a fast track approval for hPAM 4.

Recs

0
Member Avatar idahoranch (< 20) Submitted: 6/14/2009 3:08:54 PM : Outperform Start Price: $2.53 IMMU Score: -46.70

Immunomedics hPAM4 antibody for pancreatic cancer is under the radar, but nearly 50% of patients treated in the phase l trial are having good responses with tumors shrinking and the quality of life during and after treatment has been very good, unlike with most Chemo's. This could be a huge home run. The company has stated they have no intention to license this product out.

Also, UCB will be coming out with data for Epratuzumab in their dosing trials for SLE (lupus) where they are trying to find the right dose for the phase lll trials. Every trial done so far has shown Epratuzumab to have efficacy in SLE. Another sleeper.

Recs

0
Member Avatar hmcnamee (< 20) Submitted: 5/12/2009 1:32:56 AM : Outperform Start Price: $1.81 IMMU Score: +8.48

IMMU has moved to profitability over the past two quarters primarily based on the Nycomed deal. They continue to report promising results on a number of other trials for treatments of different forms of cancer. Immunomedics good cash position should provide sufficient funding in the current economic environment. Finally, the company holds an impressive portfolio of patents which seem to be undervalued by the market.

Recs

0
Member Avatar propertiusthesec (< 20) Submitted: 5/27/2008 5:19:12 PM : Outperform Start Price: $2.73 IMMU Score: +2.87

This biotech firm has a portfolio of marketable auction securities that it is selling as opportunities arise; patents and favorable phase two and three tests for drugs that improve the efficacy and reduce the deleterious effects of cancer drugs. It is currently trading above $2.60, and brokerage analysts project that it will trade at $7 within a year. It does seem to be taking a long time for management to negotiate royalty deals with major drug companies, which are said to be interested.

Recs

0
Member Avatar cancunjake (< 20) Submitted: 5/23/2008 5:08:02 PM : Outperform Start Price: $2.36 IMMU Score: +24.81

why not biotechs great place to put money . the use little gasoline

Results 1 - 20 of 33 : 1 2 Next »

Featured Broker Partners


Advertisement